Robert W. Baird Sticks to Their Buy Rating for Atreca (BCEL)
29 August 2022 - 01:16PM
TipRanks
In a report released on August 25, Joel Beatty from Robert W. Baird
maintained a Buy rating on Atreca (BCEL - Research Report), with a
price target of $9.00. The company's shares closed last Friday at
$2.11.Beatty covers the Healthcare sector, focusing on stocks such
as BioMarin Pharmaceutical, Blueprint Medicines, and Leap
Therapeutics. According to TipRanks, Beatty has an average return
of 4.4% and a 49.43% success rate on recommended stocks. Atreca has
an analyst consensus of Strong Buy, with a price target consensus
of $15.75, representing a 646.45% upside. In a report released on
August 11, Stifel Nicolaus also maintained a Buy rating on the
stock with a $12.
https://www.tipranks.com/news/blurbs/robert-w-baird-sticks-to-their-buy-rating-for-atreca-bcel?utm_source=advfn.com&utm_medium=referral
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From May 2023 to Jun 2023
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Jun 2022 to Jun 2023
